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Abstract: Xeroderma pigmentosum (XP) is a genetic disorder characterised by hypo-/hyperpigmentation, increased 
sensitivity to ultraviolet (UV)-radiation and an up to 2000-fold increased skin cancer risk. Cells from XP-patients are defec-
tive in nucleotide excision repair (NER) responsible for repair of UV-induced DNA damage. This defect accounts for their 
mutator phenotype but does not predict their increased skin cancer risk. Therefore, we carried out array analysis to measure 
the expression of more than 1000 genes after UVB-irradiation in XP cells from three complementation groups with differ-
ent clinical severity (XP-A, XP-D, XP-F) as well as from patients with normal DNA repair but increased skin cancer risk 
( 2 basal or squamous cell carcinoma at age  40yrs). Of 144 genes investigated, 20 showed differential expression with 
p   0.05 after irradiation of cells with 100 mJ/cm
2 of UVB. A subset of six genes showed a direct association of expression 
levels with clinical severity of XP in genes affecting carcinogenesis relevant pathways. Genes identiﬁ  ed in XP cells could 
be conﬁ  rmed in cells from patients with no known DNA repair defects but increased skin cancer risk. Thus, it is possible 
to identify a small gene subset associated with clinical severity of XP patients also applicable to individuals with no known 
DNA repair defects.
Keywords: array analysis, basal cell carcinoma, DNA repair, squamous cell carcinoma, skin cancer risk, xeroderma 
pigmentosum
Introduction
Xeroderma pigmentosum (XP) is an autosomal recessive disorder with an estimated prevalence of 1:10
6 
worldwide. Clinically, it is characterised by hypo- and hyperpigmentation, telangiectasia and xerosis 
of the skin.
1–3 Furthermore, patients with XP show photosensitivity and a risk to develop skin cancer 
that is increased up to 2000-fold.
4 Cells from patients with XP are defective in nucleotide excision repair 
(NER), a mechanism responsible for the repair of helix distorting DNA damage including damage 
induced by ultraviolet (UV) radiation.
5–7 While it is clear that defective DNA repair of UV-induced 
photoproducts leads to mutagenic photoproducts, this alone does not account for the increased skin 
cancer risk in these patients.
8 In line with this notion, it is known that carcinogenesis, including UV-
induced skin carcinogenesis, involves several processes such as p53 signalling, apoptosis, cell cycle 
control, DNA repair and immunosurveillance
9,10 and it has been shown that e.g. DNA repair, immunol-
ogy and apoptosis are in bidirectional cross-talk.
11,12 In support of the notion that photocarcinogenesis 
in XP patients may involve multiple factors, we have shown previously, that the absence of an increased 
skin cancer risk in two different DNA repair deﬁ  ciency syndromes, namely Trichothiodystrophy (TTD) 
and Cockayne syndrome (CS) is not associated with the DNA repair defect of these syndromes.
13
Different gene expression proﬁ  les for skin carcinogenesis have been published.
14–16 Furthermore, 
an elegant study by da Costa et al. has differentiated the transcriptional proﬁ  le in cells expressing the 
XPB/CS or XPB/TTD allele after UVC-irradiation.
17 However, thus far results derived from gene 
expression proﬁ  ling in DNA repair deﬁ  cient cells after physiologically relevant doses of UVB-irradiation 
have not been attempted to be transferred to the DNA repair proﬁ  cient background to identify a deﬁ  ned 
set of genes with functional relevance for skin carcinogenesis and possible prognostic value.2
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Investigation of differential gene expression in 
cells from patients with three different complemen-
tation groups of XP, characterized by distinct 
severities of their clinical phenotypes identiﬁ  ed a 
subset of genes with functions in processes relevant 
for UV-induced skin carcinogenesis. Genes identiﬁ  ed 
could also be detected in cells from patients with no 
known defects in DNA repair but increased skin 
cancer risk at a magnitude that continued tendencies 
discovered in DNA repair deﬁ  cient cells. The detec-
tion of this gene-subset may allow further work to 
identify factors determining the lifetime skin cancer 
risk of an individual in the normal population.
Materials and Methods
Cell culture
Fibroblast cultures were established from skin 
biopsies taken from patients with informed consent 
as approved by the ethics committee of the University 
of Düsseldorf, Germany (Nr.1480). Normal 
ﬁ  broblasts were derived from non-sunexposed skin 
of normal individuals of skin phototype II-III and 
estimated lifetime sun exposure of a caucasian 
individual in the northern hemisphere without 
outdoor occupation, and these were matched to the 
ages of the investigated patients. Xeroderma 
pigmentosum cell lines were XP19BR (XP-A), 
XP15BR (XP-A, complex splice mutation (personal 
communication A. Lehmann)), XP16BR (XP-D, 
amino acid change: R683W), XP2DF (XP-D), 
XP24BR (XP-F) and XP4DF (XP-F). These cells 
were kindly provided by Alan Lehmann from the 
Genome Stability Center of the University of Sussex 
Falmer Brighton, Great Britain with the exception 
of XP2DF and XP4DF which were generated and 
characterized by our own group. Details of the cell 
lines employed are given in Table 1. Patients 
suffering from complementation group XP-D did 
not show any features of trichothiodystrophy or 
Cockayne syndrome and patients with XP-F 
clinically showed the mildest phenotype as well as 
one XP-F patient showing the highest age, 66 years. 
Patients with  2 basal or squamous cell carcinoma 
were included in the study. Six of these patients were 
female and one male. Ages at enrolment ranged 
between 18 and 39. Numbers of tumours prior to 
enrolment ranged between 2 and 10. Primary 
ﬁ  broblasts were cultured in MEM (PAA Laboratories, 
Pasching, Austria) supplemented with 15% FCS 
(Peribo Science, Bonn, Germany) and kept at 37 °C 
in a humidiﬁ  ed atmosphere with 5% CO2. For culture 
and irradiation cells were kept in 10-cm culture 
dishes and grown to conﬂ  uency to avoid cell cycle 
inﬂ  uence.
Unscheduled DNA synthesis (UDS)
Measurement of DNA repair capacity was carried 
out similarly to the method described by Lehmann 
et al.
18 In our experiments radioactive measurement 
of 3-H-thymidine incorporation was replaced by 
peroxidase based ﬂ  uorescence measurement of 
Table 1. Details of cell lines used from patients with increased skin cancer and XP.
Patient  Group  Age  Biopsy skin site  Phototype  Sun exposure  Passage  Tumour
1   18  y  Non-sunexposed  III  Intermediate  8  BCC
2   21  y  Non-sunexposed  III  Intermediate  7  BCC
3   39  y  Non-sunexposed  II  Intermediate  2  BCC
4   29  y  Non-sunexposed  III  High  7  SCC
5   33  y  Non-sunexposed  II  Intermediate  6  BCC
6   36  y  Non-sunexposed  II  Intermediate  4  BCC
7   38  y  Sun-exposed  III  Intermediate  6  BCC
XP19BR XP-A 15  y Non-sunexposed  II-III  Low  2 
XP15BR XP-A 0.3  y  Non-sunexposed  II-III  Low  6 
XP16BR XP-D  1  y Non-sunexposed  II-III  Low  6 
XP2DF XP-D  21  y  Non-sunexposed  III  Inermediate  7 
XP24BR XP-F 30  y Non-sunexposed  I-II  Intermediate  4 
XP4DF XP-F  66  y  Non-sunexposed  II  Intermediate  8
Complementation group, age, body site of skin biopsy for ﬁ  broblast generation, skin phototype according to Fitzpatrick, estimated lifetime 
sun exposure, passage level of ﬁ  broblasts as well as the types of tumours are given where applicable. For estimated lifetime sun 
exposure low indicates close to no sun exposure at all due to XP-adequate protection, intermediate indicates sun exposure comparable 
to a caucasian individual in the northern hemisphere without occupational outdoor activity (includes XP patients applying no XP-speciﬁ  c 
sun protection) and high indicates sun exposure comparable to a caucasian individual in the northern hemisphere with occupational 
outdoor activity.3
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5-Bromo-2’-deoxy-uridine (BrdU) incorporation 
and the experimental procedure was carried out 
employing the Cell Proliferation Biotrak ELISA 
kit, version 2 (Amersham, Freiburg, Germany), 
according to the protocol. Brieﬂ  y, ﬁ  broblasts were 
plated at 1 × 10
5 in triplicates overnight followed 
by three days of serum starvation with medium 
containing 0.5% FCS. Subsequently, cells were 
exposed to 10 mM hydroxyurea for 30 min, 
washed, and then irradiated with different doses of 
UVC. Immediately after irradiation, cells were 
incubated with labelling solution including 10 µM 
BrdU for 3 hours. Labelling solution was removed 
followed by ﬁ  xation (room temperature, 30 min), 
staining with peroxidase-labelled monoclonal anti-
BrdU antibody and ﬂ  uorescence detection by an 
Emax ELISA reader (Molecular Devices, 
Workingham, Great Britain).
UVB-Irradiation
Irradiation was carried out as described previ-
ously.
19,20 Brieﬂ  y, lids were removed from tissue 
culture dishes, cells were washed with PBS once 
and irradiated with FS20 tubes (Westinghouse 
Electric, Pittsburgh, PA), which are known to emit 
primarily in the UVB range, with a tube-to-target 
distance of 22 cm and a UVB-dose of 100 mJ/cm
2. 
The UVB output was monitored by means of an 
IL1700 research radiometer and SED 240 UVB 
photodetector (International Light, Newburyport, 
MA, USA).
Array analysis
For array analysis, cells were harvested after an 
incubation time of 4 hours following UVB- or 
sham-irradiation and total RNA was extracted by 
employing the RNA Minikit (Qiagen, Hilden, 
Germany). Generation of cDNA was carried out 
employing a gene speciﬁ  c primer mix for Atlas
R 
Human 1.2 arrays (Clontech, Heidelberg, Germany) 
containing 1,185 known human genes according to 
the manufacturers protocol. Ampliﬁ  ed cDNA was 
32P-labelled and hybridised to nylon array mem-
branes for 24 hours followed by Phosphorimager
® 
(Molecular Dynamics, Heidelberg, Germany) 
analysis of signal intensities. Quantiﬁ  cation was 
carried out with AtlasImage
® Software normalizing 
values of cells from XP-patients and from patients 
with normal DNA repair but increased skin cancer 
risk to values from normal control cells, thus com-
paring normalised ratios of expression levels.
Real time RT-PCR
Real time RT-PCR was carried out by using the 
commercially available TaqMan Gene Expression 
Assay by Applied Biosystems containing 250 nM 
ﬁ  nal concentration FAM™ dye-labeled TaqMan
® 
MGB probe, 900 nm ﬁ  nal concentration unlabeled 
PCR primer oligonucleotides as well as PCR 
reagents to facilitate real time RT-PCR for inter-
leukin 2 receptor alpha, according to the manufac-
turers protocol. PCR reactions were set up in 
triplicates and performed three times separately 
for XP-patients as well as DNA repair proﬁ  cient 
patients. Data are presented as means ± SD.
Statistical analysis
For description of the repair capacity (UDS) by 
non-linear least squares we ﬁ  tted the following 
model to the data:
  ya b x =−− [] 1 exp( ) , 
where y is the UDS in %, x is the UVC-dose in 
J/cm
2, a is the asymptotic UDS for large doses and 
b is the rate of approach to the asymptotic value. 
The inverse of b multiplied by natural log of 2 
(=0.693) equals the dose D50 at which 50% of the 
asymptote is reached. For the 7 normals/patients 
matched pairs we tested whether the means of the 
difference of the parameters a and b are equal to 
zero employing one-sample t-test.
Three separate experiments were carried out for 
each cell line, expression levels of investigated 
cells were normalized to values from aged matched 
normal controls and means were generated from 
this data. Each described set of data and genes 
determined by array analysis were included in 
further statistical analysis for which at least two 
data points were available. In XP cells, for both 
cells from each complementation group this 
minimum of two data points had to be available. 
Gene expression of XP cells was compared with 
that of patients by Student´s t-test for all genes 
included in the subset of 144 genes by using the 
statistical software package JMP (www.jmp.com). 
20 of these genes showed a p-value  0.05 as 
shown in Table 2. In order to achieve normally 
distributed variates logarithmic transformations of 
the original data were used. Statistical signiﬁ  cance 
was determined by calculating the q-values for 
each gene on the basis of the corresponding 4
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p values based on the false detection rate (FDR) 
as developed for array analysis.
21 We followed 
exactly the method proposed by Storey and 
Tibshirani except that we replaced the cubic spline 
by an exponential function in determining the 
proportion of genes with no effect. In our data set, 
this method revealed p-values smaller than 0.0025 
to be statistically signiﬁ  cant (as denoted by an 
asterisk in Table 2). Of the genes with p   0.05 
six showed a direct association of gene expression 
with the clinical severity of XP complementation 
groups. These associations were illustrated by the 
95% conﬁ  dence intervals of the complementation 
group speciﬁ  c means as calculated by a one-way 
analysis of variance (Fig. 3).
Results
Conﬁ  rmation of UDS levels 
in employed cells
To ensure deﬁ  cient DNA repair in XP cells as well 
as normal repair in cells derived from patients with 
increased skin cancer risk UDS was carried out in 
the cells employed (Fig. 1a). For XP cells UDS 
was abnormal as published previously. For 
fibroblasts from normals and patients with 
increased skin cancer risk, the asymptotic value of 
UDS for large doses (10 J/cm²) did not differ 
and was within the normal range (means 
± SE: 87.1 ± 8.6% and 90.5 ± 8.3%, respectively). 
The D50 for ﬁ  broblasts from normals and patients 
were 1.04 and 2.24 respectively (Fig. 1b). The ratio 
of the two D50 values was 2.06 (95% conﬁ  dence 
interval 1.24 to 3.41; p = 0.0175). For pairs of 
patients the power for this observed difference was 
77%. In order to detect a difference of 20% in the 
asymptotic UDS value one would need 26 matched 
patients pairs with a power of 80% and a 
signiﬁ  cance level of 5%.
Identiﬁ  cation of a deﬁ  ned subset 
comprising genes with differential 
expression after UVB with 
p-values 0.05
Differential gene expression in cells from patients 
with XP complementation groups of different 
clinical severity compared to normal cells was 
measured by Atlas Human 1.2 Arrays after sham- 
or UVB-irradiation with 100 mJ/cm
2 containing 
1,185 known genes. The signal intensity for control 
housekeeping genes showed no variation between 
experiments, indicating comparable hybridization 
levels for all experiments (Fig. 2a, Array picture 
of normal cells; 2b, Array picture of XP cells). 
Detected levels of gene expression in sham 
irradiated cells did not show any patterns attributable 
to clinical severity or other parameters. However, 
when measuring expression levels in UVB-exposed 
cells, differential gene expression could be detected 
in 144 genes comprising adequate data sets. Of 
these 144 genes, a total of 20 genes showed a 
p-value 0.05 (Table 2). Most of the genes detected 
by array analysis could be classiﬁ  ed in functionally 
relevant pathways such as DNA damage signalling 
and repair, cell cycle control, apoptosis, 
protooncogenes and tumour suppressor genes, 
transcription activators and basic transcription 
factors as well as cytoskeleton/motility proteins 
(Table 2). Of these 20 genes, determination of 
positive false detection rates (pFDR) controlling 
for multiple measurements as described by Storey 
et al.
21 revealed a number of three genes (Insulin 
like growth factor, ubiquitin C, colony stimulating 
factor 1), denoted by an asterisk in Table 2, to be 
statistically signiﬁ  cant in our data set.
Association of gene expression 
levels with clinical severity of XP 
complementation groups
When comparing clinical severity of XP symptoms 
with levels of gene expression after UVB-
irradiation, a monotone association could be 
detected in six genes (Fig. 3). Of these six genes 
ﬁ  ve (Excision repair cross complementing repair 
(ERCC)-1, interleukin 2 receptor alpha, prothymosin 
alpha, hepatoma derived growth factor, tubulin 
alpha) showed an increasing tendency of gene 
expression with a low expression level in 
complementation group XP-A, intermediate 
expression level in XP-D and a high expression 
level in XP-F (Fig. 3 a). The sixth gene (ubiquitin 
C) showed a decreasing tendency of gene 
expression with high levels in XP-A, intermediate 
in XP-D and low levels of expression in XP-F, 
respectively (Fig. 3 b). The six genes showing 
association with the clinical severity of the 
XP-complementation groups involve genes in 
functionally relevant pathways including DNA 
repair (ERCC-1), immunosurveillance (interleukin 
2 receptor alpha), cell cycle control (prothymosin 6
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Figure 1. Measurement of UDS in cells from patients with at least 2 skin tumours before the age of 40. A) Assessment of UDS by 
BrdU-incorporation for ﬁ  broblasts from normal individuals, patients with increased skin cancer risk and XP-patients. Cells from patients with 
increased skin cancer and XP were age matched to normal ﬁ  broblasts e.g. F1 is matched to Patient 1 and F8 to XP19BR. All seven patients 
show normal levels of UDS with values of 50% of normal control cells or above at 10 J/cm². Cells from patients of XP complementation 
groups XP-A, XP-D and XP-F served as negative controls with values staying below 30% of normal control cells. Values for UDS-associated 
BrdU-incorporation are shown in % relative to values of control cells ±SD. B) Mean values of UDS. Data are given as means of normal and 
patient cells. The maximum value of UDS repair capacity (asymptotic value) at dose 10 J/cm² is the same in normals and patients but normal 
cells reach this value already at lower doses.7
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A) Normal
B) XP-A
C) Patient
Figure 2. Representative array membranes of unirradiated 
ﬁ  broblasts as seen after 24 h exposure of nylon membranes to 
Phosphorimager
® screens. A) Normal cells B) Cells from patient 
with XP-A; C) Cells from patient with normal DNA repair but increased 
skin cancer risk. No signiﬁ  cant differences between arrays of different 
cells without irradiation were detected. Negative control DNA and 
housekeeping genes are circled at the bottom of each array. They are 
from left to right: lambda DNA (left arrow), liver glyceraldehyde 
3-phosphate dehydrogenase (GAPDH), pUC18 DNA (right arrow), 
cytoplasmic beta-actin, 23-kDa highly basic protein, 40S ribosomal 
protein S9.
alpha), stress response (ubiquitin C), growth 
factors (hepatoma derived growth factor) as well 
as cytoskeleton/motility proteins (tubulin alpha) 
as shown in Table 2.
Conﬁ  rmation of results in XP cells 
by array analysis in cells from patient 
with no known defect in DNA repair 
but increased skin cancer risk
Genes with expression levels in association with 
the clinical severity of different XP complementation 
groups could be conﬁ  rmed in cells from patients 
with normal UDS but increased skin cancer risk 
(Fig. 3). As with XP cells, array analysis showed 
comparable expression levels for housekeeping 
controls and no discernible patterns in sham-irradi-
ated cells (Fig. 2c). In UVB-irradiated cells the 
previously detected 20 genes were also regulated 
with no association of clinical phenotype to either 
number or type of tumours or age of the patients 
(Table 3, bold; Fig. 3). Particularly, the tendency 
identiﬁ  ed in cells from different XP complementa-
tion groups was continued in these cells in an 
extrapolating manner. In all six genes expression 
levels were next to the expression levels of the 
mildest XP complementation group, XP-F 
(Fig. 3).
Conﬁ  rmation of array data by real 
time RT-PCR
The expression levels detected by array analysis 
could be conﬁ  rmed by real time RT-PCR. Figure 4 
shows gene expression levels for all genes 
identiﬁ  ed by array analysis, thus conﬁ  rming the 
data generated by array analysis (Fig. 4).
Discussion
The risk of a certain individual to develop skin 
cancer is determined by genetic and environmen-
tal factors. The exact relative inﬂ  uence of each 
factor as well as the susceptibility of one indi-
vidual to a given amount of environmental factors 
is currently unclear. These results indicate that it 
is possible to identify a deﬁ  ned subset of genes 
whose expression levels are associated with the 
clinical severity of different XP-complementa-
tion groups. Furthermore, the identiﬁ  ed genes 
can be applied to a background with no known 
defects in DNA repair but increased skin cancer 
risk.8
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Genes identiﬁ  ed by our analysis have been found 
by different approaches from other groups. Serewko 
et al. investigated the differential gene expression 
of epidermal cells during squamous cell carcinoma 
development
16 and identiﬁ  ed cell cycle genes, EGF 
receptors, calpains, growth factors, MAP kinases 
and insulin like growth factor receptors, also 
applicable to seven of the 20 genes identiﬁ  ed in our 
study. Furthermore, a study by Dong et al. 
investigated metastatic murine squamous carcinoma 
cells by differential display
22 where 3 of the six 
genes identiﬁ  ed by us to be associated with the 
clinical phenotypes of patients were the same in 
that study. Genes found to be differentially 
expressed after UVB and statistically signiﬁ  cant 
were also identiﬁ  ed by further studies.
15,23
We have previously shown that ICAM-1 expres-
sion is associated with the skin cancer risk in cells 
from patients with XP. It was unclear however, 
whether this holds true for cells from patients with 
normal DNA repair but increased skin cancer risk. 
In those studies UVB-mediated suppression of 
interferon-γ induced ICAM-1 expression was 
investigated. In the present study constitutive 
ICAM-1 expression was measured by array tech-
nology. This did not show any association of 
expression levels after UVB-irradiation with the 
clinical phenotypes of XP patients or patients with 
normal DNA repair. This is most likely due to dif-
ferences of the experimental design, since it has 
been shown that in a number of cells such as kera-
tinocytes and ﬁ  broblasts, constitutive ICAM-1 
expression can not or only at higher doses be sup-
pressed by UV-irradiation. It has to be noted that 
identiﬁ  cation of differential gene expression by 
array analysis always implies the risk of false 
positive detection or spurious association even 
though we controlled for this by performing three 
Figure 3. Identiﬁ  cation of a deﬁ  ned subset of genes with association of gene expression level and clinical severity. Gene expression 
levels of cells normalized to control cells are shown for XP-A (severe clinical phenotype), XP-D (intermediate clinical phenotype) and XP-F 
(milder clinical phenotype). Expression levels of cells from patients with normal DNA repair but increased skin cancer risk are shown next 
to the milder XP-F phenotype. A) Genes showing low levels for XP-A, intermediate levels for XP-D and high levels for XP-F. B) High level 
of gene expression in XP-A, intermediate level in XP-D and lower level in XP-F. Values for cells from XP-patients as well as values for patients 
with normal DNA repair but increased skin cancer risk were normalized to values from normal control ﬁ  broblasts and are given as natural 
logarithms of the ratios on the y-axis. The diamonds show the 95% conﬁ  dence intervals (upper and lower line) of the corresponding means 
(central line).
Tubulin alpha.
B
Ubiquitin C.10
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Table 3. Expression levels of differentially expressed genes.
Gene name p Code  XP-A XP-D XP-F Patients
Excision repair cross-compl. repair  1 (ERCC1) 0,0289096 C01n −0.143 −0.090 −0.045 −0.001
mutL (E. coli) homolog 1 0,0051168 C06n −0.110 −0.159 −0.123 0.041
CDC-like kinase1 0,0161107 A14i −0.165 −0.313 −0.140 0.054
Prothymosin, alpha (gene sequence 28) 0,0167602 A03l −0.411 −0.335 −0.203 −0.105
Ribosomal protein S19 0,0039686 A07l −0.084 −0.096 −0.023 0.095
Mitogen-activated protein kinase kinase kinase 11 0,0025372 B04k −0.093 −0.233 −0.147 0.059
Ubiquitin C* 0,0008739 G11 0.080 0.079 0.030 −0.064
v-jun avian sarcoma virus 17 homolog 0,0482950 A10c −0.016 −0.173 −0.037 0.081
Glucocorticoid receptor DNA binding factor 1 0,0364432 D07l 0.006 0.074 0.093 −0.043
EGF-response factor 1 0,0491504 D06j 0.123 0.236 0.427 0.050
Colony stimulating factor 1* 0,0010858 F03e −0.051 −0.074 −0.062 0.098
Hepatoma-derived growth factor 0,0184383 F05e −0.211 −0.133 −0.109 0.026
Interleukin 2 receptor, alpha 0,0153361 E01l −0.412 −0.369 −0.157 −0.050
Interleukin 1, beta 0,0068164 F10i −0.173 −0.128 −0.131 −0.046
Ribosomal protein L13a 0,0371257 G45 −0.163 −0.248 −0.156 −0.015
Major histocompatibility complex, class I, C 0,0305518 G31 −0.479 −0.233 −0.320 −0.039
Tubulin alpha 0,0246099 G29 −0.418 −0.338 −0.182 −0.139
Calpain 2, (m/II) large subunit 0,0390684 C14h −0.135 −0.059 −0.062 0.023
Insulin-like growth factor binding protein 3* 0,0002142 F12h 1.045 1.253 1.220 0.389
Heat shock 27kD protein 1 0,0381607 F05b −0.115 0.053 −0.036 0.096
Expression levels of genes are shown for patients with XP-A, XP-D, XP-F and patients with normal DNA repair but increased skin 
cancer risk. Genes with correlation to clinical severity of XP complementation groups as well as patients with normal DNA repair and 
increased skin cancer risk are shown in bold. Data is presented as means of three separate experiments from two cell lines of XP 
patients and seven patients with increased skin cancer risk normalized to age matched normal cells. P-values of respective genes are 
given as generated by Student´s t test and only genes with a p-value <0.05 are listed
independent experiments for two XP-cell lines and 
seven patients with normal DNA repair and statis-
tical evaluation of positive false detection rate.
21 
Bearing all this in mind, however, these results 
may nevertheless indicate, that the investigation 
of a single gene e.g. ICAM-1, may be sufﬁ  cient to 
distinguish between cancer prone XP and non-
cancer prone TTD but it may not be sufﬁ  cient to 
identify an increased skin cancer risk in individu-
als with no known defects in DNA repair capacity. 
In our present study, simultaneous measurement 
of 1,185 genes by array technology did reveal six 
genes that are indeed associated with the skin 
cancer risk of investigated individuals. This may 
indicate a higher sensitivity of array assessment as 
compared to measurement of any single gene, this 
being the case even in a background with no known 
defects in DNA repair.
In the present study the NER gene ERCC-1 
was found to be associated with the clinical 
phenotypes of DNA repair deﬁ  cient and proﬁ  cient 
patients. Since it has been shown previously that 
expression of NER genes such as XPC and XPE 
can be transactivated by p53 after UV-radiation
30 
the present data conﬁ  rm the notion that NER 
genes can be differentially expressed and that they 
may be associated with the clinical phenotype not 
only in XP patients but also in individuals with 
no known defect in DNA repair but increased skin 
cancer risk. Genes identified by a study 
investigating differential gene expression in cells 
with the XPB/CS or XPB/TTD allele
17 also 
conﬁ  rmed genes identiﬁ  ed by our work (tubulin 
alpha, MHC-I, Insulin like growth factor) albeit 
this study employed UVC-irradiation.
Investigation of differential gene expression 
analysis has been carried out extensively previ-
ously with the intention to identify genes regu-
lated by ultraviolet radiation or during skin 
carcinogenesis.
14–16,22,24–27 In the present study 
this intention was only secondary. One of the 
strengths of array analysis is their application as 
a diagnostic technology.
28,29 The present work 
identiﬁ  ed a restricted and deﬁ  ned subset of genes 
generated from well established syndromes. 
These genes were then transferred to a back-
ground with no known defect in DNA repair. 
Further studies are necessary to evaluate the 
prognostic value of this gene subset in the normal 
population.11
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Figure 4. Real time RT-PCR for conﬁ  rmation of data generated by array analysis. Expression levels in two cell lines from patients with 
XP-A, XP-D, XP-F and all cells from individuals with no known defect in DNA repair but increased skin cancer risk (Patients). The logarithms 
of the data are presented as means +/− SD of three separate experiments. Expression levels determined by RT-PCR parallel levels detected 
by array analysis (compare Fig. 3).
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